Clopidogrel beneficial during acute phase of MI; metoprolol has no overall effect
May 1st 2005Clopidogrel reduces 28-day mortality in the treatment of patients with acute myocardial infarction (MI) when given on top of standard therapies, but metoprolol has no effect on in-hospital mortality when given during the acute phase of MI.
Read More
Drug-eluting stent comparisons give slight edge to sirolimus-eluting sent
May 1st 2005In-lesion restenosis is similar between the sirolimus-eluting stent (Cypher) and the paclitaxel-eluting stent (Taxus) when used for the treatment of routine coronary artery stenoses, but the sirolimus-eluting stent may offer an advantage in patients with diabetes, according to a study reported at the ACC Annual Scientific Session 2005.
Read More
Calcium antagonist has clinical advantage over beta-blocker as initial antihypertensive therapy
May 1st 2005An antihypertensive therapeutic strategy that starts with the calcium antagonist amlodipine is superior to one starting with the beta-blocker atenolol in preventing coronary heart disease (CHD) events, Peter S. Sever, MD, reported at the ACC Annual Scientific Session 2005.
Read More
Evidence supports high-dose over low-dose atorvastatin in stable coronary heart disease
May 1st 2005Atorvastatin 80 mg/d is associated with better cardiovascular outcomes than atorvastatin 10 mg/d in patients with stable coronary heart disease (CHD), according to John LaRosa, MD, who presented the results of the Treating to New Targets (TNT) study at the ACC Annual Scientific Session 2005.
Read More
Secondary stroke prophylaxis: ARB bests calcium antagonist
May 1st 2005The angiotensin receptor blocker (ARB) eprosartan is superior to the calcium antagonist nitrendipine in secondary stroke prophylaxis in patients with hypertension, Hans-Christian Diener, MD, reported at the ASA's International Stroke Conference 2005.
Read More
Ramelteon: A novel melatonin receptor agonist for the treatment of insomnia
May 1st 2005Ramelteon (Takeda Pharmaceuticals) is a selective melatonin receptor agonist awaiting FDA approval for the treatment of insomnia. Unlike the currently prescribed hypnotic agents that work by targeting gamma-aminobutyric acid (GABA) receptors, ramelteon offers a novel mechanism of action, specifically targeting the MT1 and MT2 receptors in the brain, which are thought to play a role in regulating sedation and circadian rhythms. Ramelteon is characterized by undergoing extensive first-pass metabolism along with having high oral bioavailability. Results of phase 2 clinical trials have demonstrated that ramelteon-treated patients had significantly shorter sleep onset latencies and longer total sleep times than placebo-treated patients. Furthermore, ramelteon therapy did not appear to impair patient cognition, memory recall, levels of alertness, or ability to concentrate. Data from animal studies suggest that ramelteon is not likely to cause abuse or physical dependence. Unlike the current FDA-approved..
Read More
If approved, tipranavir (Boehringer Ingelheim) will be the ninth protease inhibitor (PI) available and the first nonpeptidic PI available in the United States. Designed by structure-based analysis, tipranavir is more flexible at the binding site, allowing for a potent and durable antiretroviral response. The tipranavir (TPV) and ritonavir (RTV) PI regimen (TPV/r) studied in clinical trials had a moderate pill burden, requiring 4 pills to be taken twice daily (2 RTV 100 mg and 2 TPV 250 mg).
Read More
A timely transition to insulin: Identifying type 2 diabetes patients failing oral therapy
April 1st 2005Although oral antidiabetic medications initially may be effective for controlling hyperglycemia, these agents often fail to maintain adequate glycemic control as the disease progresses, and insulin eventually is required in most patients. This review explores strategies for identifying patients with type 2 diabetes who are failing to maintain glycemic control on oral agents and for transitioning these patients to insulin. Based on available data, patients are not reaching recommended glycemic goals due to delays in and reluctance towards intensification of therapy, resulting in an increased risk of complications.
Read More
At first glance, you might wonder what the Japanese auto industry has to do with managed healthcare in the United States. For Anthony Horbal (pictured left), founder and CEO of Erie, Pa.-based Ion Health Inc. and Mike Nelson, Ion Health's president and director, Japanese automakers just might have provided an epiphany.
Read More
Levodopa remains principal treatment for Parkinson's disease
April 1st 2005Parkinson's Disease is a chronic, progressive neurological disorder that occurs when neurons in the part of the brain that controls movement start to degenerate. This leads to a shortage of the neurotransmitter dopamine, causing characteristic movement problems.
Read More
At first glance, you might wonder what the Japanese auto industry has to do with managed healthcare in the United States. For Anthony Horbal (pictured left), founder and CEO of Erie, Pa.-based Ion Health Inc. and Mike Nelson, Ion Health's president and director, Japanese automakers just might have provided an epiphany.
Read More
Innovative programs help Medicaid recipients thrive
April 1st 2005Not long ago, I was talking with a family friend, Jamie, a young, single mom and then Medicaid recipient. We were discussing our families and I had mentioned how busy I was driving my children to and from their many extracurricular activities and social events.
Read More